{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018807","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.635572+00:00","generated_at":"2026-06-15T13:59:01.599110+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ORIC reports Q1 cash $208.9M; three Phase 1b data readouts expected H2 2023","bullets":["Cash and investments $208.9M as of March 31, 2023; funds operations into H1 2025.","R&D expenses $19.5M (up $2.7M YoY) driven by clinical and discovery program advancement.","G&A expenses $6.2M, down $0.3M YoY.","Initial Phase 1b data expected H2 2023 for ORIC-533 (myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate).","Preclinical data for ORIC-944 biomarker strategy and PLK4 program presented at AACR 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018807","json":"https://secwatch.observer/filing/0000950170-23-018807.json","markdown":"https://secwatch.observer/filing/0000950170-23-018807.md","text":"https://secwatch.observer/filing/0000950170-23-018807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023018807/0000950170-23-018807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023018807/oric-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:59:01.599110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4f64ecf904367a09308aa62e12f99bdb4787a75","claim":"Oric Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 8, 2023, ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023018807/0000950170-23-018807-index.htm","confidence":0.1,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}